Apriso approved for ulcerative colitis

The FDA has approved Apriso (mesalamine extended-release capsules, from Salix) for remission maintenance of ulcerative colitis (UC) in adults. In two randomized, double-blind, placebo-controlled studies involving 562 patients, Apriso was more effective in maintaining long-term UC remission and sustaining improvement of UC symptoms for six months than placebo.

Apriso is expected to launch during the first quarter of 2009 in 0.375g dosage strength.

For more information call (800) 508-0024 or visit www.salix.com.